Specificity requirement for FDC and concomitant medication [Bioanalytics]

posted by qualityassurance – 2023-07-07 11:06 (317 d 04:43 ago) – Posting: # 23659
Views: 1,235

Hi Karthik,

My opinion is that your validation should mimic the actual study condition. In BE studies of FDC, plasma samples contains all the analytes of interest and hence CC/QC during validation should contain the other analyte at ULOQ concentration or cmax concentration.

What is opinion of other (bioanalytical) experts?

Regards,
qualityassurance

Complete thread:

UA Flag
Activity
 Admin contact
23,029 posts in 4,834 threads, 1,644 registered users;
32 visitors (0 registered, 32 guests [including 4 identified bots]).
Forum time: 15:49 CEST (Europe/Vienna)

We must be careful not to confuse data with the abstractions
we use to analyze them.    William James

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5